Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 19, 2021

Primary Completion Date

December 30, 2025

Study Completion Date

April 30, 2026

Conditions

Down SyndromeDown Syndrome, Partial Trisomy 21Alzheimer Disease

Interventions

DRUG

[18F]-FEOBV Radiotracer

Participants will be administered an \[18F\]-fluoroethoxybenzovesamicol (FEOBV) radiotracer for diagnostic imaging purposes (PET scan).

Trial Locations (1)

Vanderbilt University Medical Center Clinical Research Center, Nashville

All Listed Sponsors

collaborator

Vanderbilt Kennedy Center

OTHER

lead

Vanderbilt University Medical Center

OTHER